Dr. Piccart on Metagene Prognostic Signatures

Martine Piccart, MD, PhD
Published: Wednesday, Mar 27, 2013

Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, discusses the development of metagene prognostic signatures for patients with breast cancer.

Piccart is not sure that metagene prognostic signatures can get any better as years have been spent developing what currently exists.

Piccart says there may be one exception in the case of Endopredict. This signature predicts for excellent long-term outcome and disease-free survival at 10 years. Endopredict has been validated in the context of large, randomized, "clean" clinical trials, according to Piccart.

Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, discusses the development of metagene prognostic signatures for patients with breast cancer.

Piccart is not sure that metagene prognostic signatures can get any better as years have been spent developing what currently exists.

Piccart says there may be one exception in the case of Endopredict. This signature predicts for excellent long-term outcome and disease-free survival at 10 years. Endopredict has been validated in the context of large, randomized, "clean" clinical trials, according to Piccart.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x